150 related articles for article (PubMed ID: 32531259)
1. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
Lawitz E; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson R; Maliakkal BJ; Gordon SC; Gane EJ
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):918-926. PubMed ID: 32531259
[TBL] [Abstract][Full Text] [Related]
2. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.
Osinusi A; Kohli A; Marti MM; Nelson A; Zhang X; Meissner EG; Silk R; Townsend K; Pang PS; Subramanian GM; McHutchison JG; Fauci AS; Masur H; Kottilil S
Ann Intern Med; 2014 Nov; 161(9):634-8. PubMed ID: 25364884
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
[TBL] [Abstract][Full Text] [Related]
4. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
[TBL] [Abstract][Full Text] [Related]
5. Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study.
Wei L; Xie Q; Hou JL; Tang H; Ning Q; Cheng J; Nan Y; Zhang L; Li J; Jiang J; McNabb B; Zhang F; Camus G; Mo H; Osinusi A; Brainard DM; Gong G; Mou Z; Wu S; Wang G; Hu P; Gao Y; Jia J; Duan Z
Hepatol Int; 2018 Mar; 12(2):126-132. PubMed ID: 29637511
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
Sulkowski MS; Naggie S; Lalezari J; Fessel WJ; Mounzer K; Shuhart M; Luetkemeyer AF; Asmuth D; Gaggar A; Ni L; Svarovskaia E; Brainard DM; Symonds WT; Subramanian GM; McHutchison JG; Rodriguez-Torres M; Dieterich D;
JAMA; 2014 Jul 23-30; 312(4):353-61. PubMed ID: 25038354
[TBL] [Abstract][Full Text] [Related]
7. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
Naggie S; Fierer DS; Hughes MD; Kim AY; Luetkemeyer A; Vu V; Roa J; Rwema S; Brainard DM; McHutchison JG; Peters MG; Kiser JJ; Marks KM; Chung RT;
Clin Infect Dis; 2019 Jul; 69(3):514-522. PubMed ID: 31220220
[TBL] [Abstract][Full Text] [Related]
8. Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).
Lacombe K; Moh R; Chazallon C; Lemoine M; Sylla B; Fadiga F; Le Carrou J; Marcellin F; Kouanfack C; Ciaffi L; Sartre MT; Sida MB; Diallo A; Gozlan J; Seydi M; Cissé V; Danel C; Girard PM; Toni TD; Minga A; Boyer S; Carrieri P; Attia A;
Sci Rep; 2024 May; 14(1):10244. PubMed ID: 38702350
[TBL] [Abstract][Full Text] [Related]
9. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.
Latt NL; Yanny BT; Gharibian D; Gevorkyan R; Sahota AK
World J Gastroenterol; 2017 Jul; 23(26):4759-4766. PubMed ID: 28765697
[TBL] [Abstract][Full Text] [Related]
10. Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.
Kohli A; Kattakuzhy S; Sidharthan S; Nelson A; McLaughlin M; Seamon C; Wilson E; Meissner EG; Sims Z; Silk R; Gross C; Akoth E; Tang L; Price A; Jolley TA; Emmanuel B; Proschan M; Teferi G; Chavez J; Abbott S; Osinusi A; Mo H; Polis MA; Masur H; Kottilil S
Ann Intern Med; 2015 Dec; 163(12):899-907. PubMed ID: 26595450
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
Sulkowski MS; Vargas HE; Di Bisceglie AM; Kuo A; Reddy KR; Lim JK; Morelli G; Darling JM; Feld JJ; Brown RS; Frazier LM; Stewart TG; Fried MW; Nelson DR; Jacobson IM;
Gastroenterology; 2016 Feb; 150(2):419-29. PubMed ID: 26497081
[TBL] [Abstract][Full Text] [Related]
12. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.
Wilson EM; Kattakuzhy S; Sidharthan S; Sims Z; Tang L; McLaughlin M; Price A; Nelson A; Silk R; Gross C; Akoth E; Mo H; Subramanian GM; Pang PS; McHutchison JG; Osinusi A; Masur H; Kohli A; Kottilil S
Clin Infect Dis; 2016 Feb; 62(3):280-288. PubMed ID: 26521268
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
Lawitz E; Poordad F; Brainard DM; Hyland RH; An D; Dvory-Sobol H; Symonds WT; McHutchison JG; Membreno FE
Hepatology; 2015 Mar; 61(3):769-75. PubMed ID: 25322962
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.
Kim YM; Kim SB; Song IH; Lee SH; Kim HS; Lee TH; Kang YW; Kim SH; Lee BS; Chae HB; Song MJ; Jang JW; Ko SY; Lee JD
Clin Mol Hepatol; 2018 Sep; 24(3):311-318. PubMed ID: 29865774
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Zhang S; Bastian ND; Griffin PM
BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358
[TBL] [Abstract][Full Text] [Related]
16. Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancies: A Pharmacokinetic Study.
AbdelMagid AM; Abbassi MM; Ebeid FS; Farid SF; El-Sayed MH
Clin Ther; 2024 Jan; 46(1):e12-e22. PubMed ID: 37925363
[TBL] [Abstract][Full Text] [Related]
17. Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir.
Wang XX; Luo BF; Jiang HJ; Cong X; Jin Q; Ma DL; Wei L; Feng B
World J Gastroenterol; 2018 Oct; 24(40):4554-4564. PubMed ID: 30386105
[TBL] [Abstract][Full Text] [Related]
18. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
Hundemer GL; Sise ME; Wisocky J; Ufere N; Friedman LS; Corey KE; Chung RT
Infect Dis (Lond); 2015; 47(12):924-9. PubMed ID: 26365684
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Chhatwal J; Kanwal F; Roberts MS; Dunn MA
Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.
Wyles D; Bräu N; Kottilil S; Daar ES; Ruane P; Workowski K; Luetkemeyer A; Adeyemi O; Kim AY; Doehle B; Huang KC; Mogalian E; Osinusi A; McNally J; Brainard DM; McHutchison JG; Naggie S; Sulkowski M;
Clin Infect Dis; 2017 Jul; 65(1):6-12. PubMed ID: 28369210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
